Supplemental Fig. S9 from Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells
Year: 2026
Type: supplementary-materials
Abstract: Supplemental Fig. S9. Trametinib reprograms the KPC-FIO tumors toward a less immunosuppressive tumor immune microenvironment (TiME). A-D. Mice with established 2138-FIO (A, B) and 2138 (C, D) tumors were treated with either DMSO as vehicle control or Trametinib (1 mg/kg, daily). At study endpoint, tumors were processed and analyzed by flow cytometry for the frequency of monocytic myeloid derived suppressive cells (M-MDSCs; CD45+CD11b+Ly6G−Ly6C+), granulocytic myeloid derived suppressive cells (G-MDSCs; CD45+CD11b+Ly6G+Ly6C−), and tumor-associated macrophages (TAMs; CD45+CD11b+F4/80+) (A, C), and their immunosuppressive markers (CD206, PD-L1, Arginase1 (Arg1)) (B, D). Error bars ± SEM. Unpaired t-test. *, p<0.05 **, p<0.01 ***, p<0.001 ns, non-significant. E. Slice cultures from neoadjuvant FOLFIRINOX-treated human tumors (n=3) were treated with either DMSO or Trametinib (5 µM). After 96 hours, slices were collected and analyzed for CD206 and Arginase1 (Arg1) expression by immunohistochemistry staining. Scale bar 100 μm. The number of positive cells were quantified by ImageJ and analyzed by GraphPad. Paired t-test. *, p<0.05.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7165061546